Genentech Shows Off Positive Results From Phase III HEMLIBRA, TECENTRIQ Studies Post author:Sam Post published:November 19, 2017 Post category:BioPharma Data will be submitted to health authorities globally, including the FDA and EMA. Source: BioSpace You Might Also Like FDA Hails Novartis' Kisqali a Breakthrough January 2, 2018 Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 February 1, 2018 <b>Phosphorus</b> Announces Formation Of Scientific Advisory Board February 28, 2017
Alder BioPharmaceuticals Announces Closing of $250M of 2.50% Convertible Senior Notes Due 2025 February 1, 2018
